Skip to main content
SpringerLink
Log in
Book cover

Cancer in Transplantation: Prevention and Treatment pp 249–258Cite as

Increased risk of lymphoproliferative disorders following the use of OKT3: Association with cumulative dose

  • Chapter

  • 57 Accesses

Part of the book series: Transplantation and Clinical Immunology ((TRAC,volume 27))

Abstract

Post-transplantation lymphoproliferative disorder (PTLD) is a frequently fatal complication of immunosuppression [1]. The term describes Epstein–Barr virus associated B-lymphoproliferations occurring after organ transplantation. The disease has assumed increasing clinical importance in view of the constantly rising number of organ transplant recipients and the development of highly potent and specific immunosuppressive drugs. Continued, uncontrolled EBV-driven proliferation of B-cells in the absence of adequate T-cell control has been proposed as a mechanism for the development of PTLD by Klein and others [2, 3]. As proliferation continues, clones with a growth advantage emerge, and a monoclonal population eventually predominates. This model is capable of at least partially explaining many of the otherwise puzzling clinical and pathologic features of this disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Current Problems In Surgery 1988; 25: 367–472.

    Article  PubMed  CAS  Google Scholar 

  2. Purtilo DT. Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet 1980; 1: 300–303.

    Article  PubMed  CAS  Google Scholar 

  3. Klein G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proceedings of the National Academy of Sciences of the United States of America 1979; 76: 2442–2446.

    Article  PubMed  CAS  Google Scholar 

  4. Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. Journal of Heart & Lung Transplantation 1991; 10: 877–886.

    CAS  Google Scholar 

  5. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583–587.

    Article  PubMed  CAS  Google Scholar 

  6. Beveridge T, Krupp P, McKibbin C. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy [letter]. Lancet 1984; 1: 788.

    Article  PubMed  CAS  Google Scholar 

  7. Penn I. Malignant lymphomas in organ transplant recipients. Transplantation Proceedings 1981; 13: 736–738.

    PubMed  CAS  Google Scholar 

  8. Cleary ML, Warnke R, Sklar J. Monoclonality of lymphoproliferative lesions in cardiactransplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements. New England Journal of Medicine 1984; 310: 477–482.

    Article  PubMed  CAS  Google Scholar 

  9. Nalesnik MA, Jaffe R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. American Journal of Pathology 1988; 133: 173–192.

    PubMed  CAS  Google Scholar 

  10. Bach JF, Chatenoud L. Immunologic monitoring of Orthoclone OKT3-treated patients: the problem of antimonoclonal immune response. Transplantation Proceedings 1987; 19: 17–20.

    PubMed  CAS  Google Scholar 

  11. Costanzo-Nordin MR, Silver MA, O’Connell JB et al. Successful reversal of acute cardiac allograft rejection with OKT monoclonal antibody. Circulation 1987; 76: V71-V80.

    PubMed  CAS  Google Scholar 

  12. Renlund DG, O’Connell JB, Gilbert EM et al. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3. Transplantation 1989; 47: 599–605.

    Article  PubMed  CAS  Google Scholar 

  13. Barr ML, Sanchez JA, Seche LA, Schulman LL, Smith CR, Rose EA. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation. Circulation 1990; 82: IV291-IV294.

    PubMed  CAS  Google Scholar 

  14. Witherspoon RP, Fisher LD, Schoch G et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia [see comments]. New England Journal of Medicine 1989; 321: 784–789.

    Article  PubMed  CAS  Google Scholar 

  15. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. New England Journal of Medicine 1990; 323: 1723–1728.

    Article  PubMed  CAS  Google Scholar 

  16. Billingham ME. Some recent advances in cardiac pathology. Human Pathology 1979; 10: 367–386.

    Article  PubMed  CAS  Google Scholar 

  17. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135.

    Google Scholar 

  18. Ho M, Miller G, Atchison RW et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. Journal of Infectious Diseases 1985; 152: 876–886.

    Article  PubMed  CAS  Google Scholar 

  19. Swinnen LJ, Fisher SG, Fisher RI, Koch D, Costanzo MR. Elimination Of OKT3 Induction Therapy: Impact On The Incidence Of Lymphoma Following Cardiac Transplantation. J Heart Lung Transplant 1994; 13 No. 1(2)(abs 148): S68 (abstract).

    Google Scholar 

  20. Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. [Review]. Current Opinion in Nephrology & Hypertension 1993; 2: 670–678.

    CAS  Google Scholar 

  21. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529.

    PubMed  CAS  Google Scholar 

  22. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234–1243.

    PubMed  CAS  Google Scholar 

  23. Alfrey EJ, Friedman AL, Grossman RA et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder Transplantation 1992; 54: 250–253.

    CAS  Google Scholar 

  24. Cockfield SM, Preiksaitis J, Harvey E et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplantation Proceedings 1991; 23: 1106–1107.

    PubMed  CAS  Google Scholar 

  25. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplantation Proceedings 1991; 23: 1473–1476.

    PubMed  CAS  Google Scholar 

  26. Rosenthal JT, Wilkinson AH, Canfield CW. Fulminant Epstein-Barr Virus-Associated Post-Transplant lymphoproliferative Disorders Following OKT3 Therapy. ASTP Annual Meeting 1991; 74 (abs).

    Google Scholar 

  27. Rinde-Hoffman D, Cintron GB, Ferguson JE, Toole JC, Bugni WB. Lymphoproliferative disorder early after cardiac transplantation [published erratum appears in Am J Cardiol 1992 Mar 15; 69(8): 844]. American Journal of Cardiology 1991; 68: 1724–1725.

    Article  PubMed  CAS  Google Scholar 

  28. Penn I. The changing pattern of posttransplant malignancies. Transplantation Proceedings 1991;23: 1101–1103.

    PubMed  CAS  Google Scholar 

  29. Ren EC, Chan SH. Possible enhancement of Epstein-Barr virus infections by the use of OKT3 in transplant recipients. Transplantation 1988; 45: 988–989.

    Article  PubMed  CAS  Google Scholar 

  30. Bird AG, McLachlan SM, Britton S. Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1981; 289: 300–301.

    Article  PubMed  CAS  Google Scholar 

  31. Emery RW, Lake KD. Post-transplantation Lymphoproliferative Disorder and OKT3 (let.). N Engl J Med 1991; 324: 1437.

    Article  Google Scholar 

Download references

Authors
  1. Lode J. Swinnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hôpital Edouard Herriot, Pavillon P, 5, Place d’Arsonval, 69437, Lyon 3, France

    J. L. Touraine

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Swinnen, L.J. (1996). Increased risk of lymphoproliferative disorders following the use of OKT3: Association with cumulative dose. In: Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Cancer in Transplantation: Prevention and Treatment. Transplantation and Clinical Immunology, vol 27. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0175-9_28

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0175-9_28

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6563-4

  • Online ISBN: 978-94-009-0175-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation